CapsoVision Inc. (NASDAQ: CV) Q2 2025 Earnings Call | 08/15/2025
AI Summary
Capsocam Plus: Their FDA-cleared capsule for small bowel visualization is already in commercial use.
It has been used by over 143,000 patients total.
Q2 2025 saw 17% year-over-year growth, with approximately 7,900 patients using the system.
The company is seeing strong growth in new accounts, hospital systems, and large GI groups.
Revenue: $3.3 million, up 17% from Q2 2024.
Gross Margin: 55%.
Net Loss: $4.6 million, improved from a $5.3 million loss in Q2 2024.
Cash: Ended the quarter with $1.1 million, but subsequently completed an IPO in July, receiving net proceeds of $23.4 million.
AI Module for Capsocam Plus: Submission to the FDA planned for late September/early October 2025, with a potential launch in Q1 2026. This AI is developed in-house, which the company sees as a key strategic advantage.
Capsocam Colon: A non-invasive capsule for colon polyp detection.
A submission for the first-generation colon capsule was made to the FDA in June 2025.
However, the company plans to commercialize an improved second-generation (Gen 2) capsule with 35% more viewing area and better image quality, which it expects to submit for FDA approval in Q1 2026.
This targets an estimated $1+ billion market for patients unable or unwilling to undergo traditional colonoscopy.
Pancreas Screening: Leveraging their capsule's high detection rate of a key pancreatic landmark, they plan to apply for Breakthrough Device Designation by year-end to accelerate development for pancreatic cancer screening.
Esophageal Varices Screening: Pivotal studies for screening varices in cirrhosis patients are planned for the second half of 2026.
Recent FDA clearances now allow Capsocam Plus use in pediatric patients (as young as 2) and for remote ingestion at home via telemedicine.
The company announced a $4.1 million development agreement with Canon to design a next-generation image sensor for future capsules.
Company & Mission: CapsoVision is a public company focused on developing non-invasive, ingestible capsule endoscopy systems for early disease screening in the GI tract. Their mission is to provide a patient-friendly alternative to traditional procedures.
Key Product & Commercial Update:
Financial Performance (Q2 2025):
Development Pipeline & Future Catalysts:
Other Highlights:
About this video
CapsoVision Inc. released its Q2 2025 financial results showing a 17% increase in GAAP revenue to $3.3 million, slightly exceeding analyst estimates amid growing adoption of its CapsoCam Plus capsule endoscopy system, now used by over 143,000 patients as of June 30, 2025. New customer accounts surged 75% year-over-year, reflecting accelerated clinical adoption globally. However, the company reported a GAAP net loss per share of $2.02, wider than the estimated $0.11 loss, driven by ongoing high operating expenses despite a 6% reduction year-over-year, chiefly due to the conclusion of major clinical trials. Operating losses remained elevated at $4.65 million. CapsoVision’s strategic focus includes advancing its product pipeline with the CapsoCam Colon device, which received FDA submission, and developing an AI-powered image analysis module to improve diagnostic capabilities and expand into new indications. The company bolstered its financial position significantly with a $23.4 million IPO in July 2025, enabling continued investment in technology innovation and regulatory approvals. Management emphasized commitment to growing market penetration, clinical adoption, and operational efficiencies as it navigates competitive pressures in the minimally invasive endoscopy market. About Inside Ticker: Inside Ticker delivers precise, in-depth earnings coverage and market analysis for investors and industry professionals. Visit us at https://www.insideticker.com/ #CapsoVision #CV #Q22025 #Earnings #MedicalTechnology #CapsuleEndoscopy #RevenueGrowth #NetLoss #ClinicalAdoption #FDA #ArtificialIntelligence #HealthcareInnovation #IPO #Diagnostics #MedicalDevices #StockMarket #Investment #EarningsCall #FinancialResults #HealthcareTech
Video Stats
More from this category

Dell Technologies Inc. (NYSE: DELL) Q1 2026 Earnings Call | AI Server Demand | 5/30/2025
Inside Ticker

Mama's Creations, Inc. (NASDAQ: MAMA) Q1 2026 Earnings Call | 6/3/2025
Inside Ticker

Sportsman’s Warehouse Holdings, Inc. (NASDAQ: SPWH) Q1 2025 Earnings Call | 6/3/2025
Inside Ticker

Hewlett Packard Enterprise Company (NYSE: HPE) Q2 2025 Earnings Call | 6/3/2025
Inside Ticker

Yext, Inc. (NYSE: YEXT) Q1 2026 Earnings Call | 6/3/2025
Inside Ticker

Elastic N.V. (NYSE: ESTC) Q4 2025 Earnings Call | Cloud Revenue Surges & AI Platform | 5/30/2025
Inside Ticker

CrowdStrike Holdings, Inc. (NASDAQ: CRWD) Q1 2026 Earnings Call | 6/3/2025
Inside Ticker

Zscaler (ZS) Q3 2025 Earnings Call | Revenue Beats & AI Security Highlights | May 2025
Inside Ticker

BARK, Inc. (NYSE: BARK) Q4 2025 Earnings Call | 6/4/2025
Inside Ticker

lululemon athletica inc. (NASDAQ: LULU) Q1 2025 Earnings Call | 6/5/2025
Inside Ticker

Sprinklr, Inc. (NYSE: CXM) Q1 2026 Earnings Call | 6/4/2025
Inside Ticker

Braze, Inc. (NASDAQ: BRZE) Q1 2026 Earnings Call | 6/5/2025
Inside Ticker
